Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
BioNexus Gene Lab's Enterprise Value for the quarter that ended in Mar. 2026 was $1.42 Mil.
BioNexus Gene Lab's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.89 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioNexus Gene Lab EV-to-EBIT Related Terms
BioNexus Gene Lab EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for BioNexus Gene Lab's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Specialty Chemicals subindustry, BioNexus Gene Lab's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioNexus Gene Lab EV-to-EBIT vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, BioNexus Gene Lab's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where BioNexus Gene Lab's EV-to-EBIT falls into.
BioNexus Gene Lab's current Enterprise Value is $0.22 Mil.
BioNexus Gene Lab's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.89 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioNexus Gene Lab (BGLC) has a EV-to-EBIT of -0.07 as of Aug. 08, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on BioNexus Gene Lab and its competitors. According to the industry distribution chart, BioNexus Gene Lab ranks #999999 out of 1243 companies in the Chemicals industry.
Is BioNexus Gene Lab's EV-to-EBIT too high?
BioNexus Gene Lab's current EV-to-EBIT is -0.07. Based on the distribution chart, BioNexus Gene Lab ranks #999999 out of 1243 companies in the Chemicals industry, which is in the bottom quartile relative to peers. Overall, BioNexus Gene Lab has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioNexus Gene Lab's EV-to-EBIT compare to VYST and QGAI?
According to the Chemicals industry distribution chart, BioNexus Gene Lab ranks #999999 out of 1243 companies for EV-to-EBIT. This places BioNexus Gene Lab in the lower half of its industry. The industry median EV-to-EBIT is 17.59. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Chemicals company?
The median EV-to-EBIT among Chemicals companies is 17.59, based on 1,243 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on BioNexus Gene Lab and its competitors. For the Chemicals industry, the median EV-to-EBIT is 17.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioNexus Gene Lab's current EV-to-EBIT is -0.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioNexus Gene Lab stock overvalued right now?
Based on GuruFocus' analysis, BioNexus Gene Lab (BGLC) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.15, compared to a current price of $1.57 — trading 27% below its estimated fair value. The current EV-to-EBIT is -0.07. BioNexus Gene Lab's overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For BioNexus Gene Lab (BGLC), the current EV-to-EBIT is -0.07 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioNexus Gene Lab (BGLC) Overvalued in 2026?
Based on GuruFocus' analysis, BioNexus Gene Lab stock appears to be undervalued.
The current stock price of $1.57 is trading 27% below its estimated GF Value™ of $2.15.
GuruFocus considers BioNexus Gene Lab to be Modestly Undervalued.
Key valuation signals for BGLC:
EV-to-EBIT: -0.07
GF Value™: $2.15 vs. price of $1.57 (27% below fair value)
No single metric tells the full story. See the BGLC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioNexus Gene Lab Corp is a Wyoming corporation with two principal operating subsidiaries in Malaysia: Chemrex Corporation Sdn. Bhd. (Chemrex) and MRNA Scientific Sdn. Bhd. (MRNA Scientific). Chemrex is engaged in the distribution of chemical raw materials, mainly for industrial applications in Southeast Asia. MRNA Scientific is engaged in the development and provision of blood-based genomic screening services intended to support early disease risk assessment and health management. Trading of industrial chemicals- Includes trading of industrial chemicals. Provision for genomic screening services- includes in commercializing proprietary blood-based diagnostic test for early disease detection. Investment holding- Investment holding, are its segments.
58GF Score
Get the complete analysis for BGLC
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BGLC has been successfully added to your 
